American Society For Nanomedicine

This review summarized the mechanism of a novel fusion protein (PHPV fusion protein) containing membrane penetrating peptide and oligopeptide-1 (EGF). The new PHPV fusion protein contains two kinds of polypeptides: membrane penetrating peptide and oligopeptide-1, so it has a good function of preventing and treating HPV virus. PHPV fusion protein not only has the multi effect function of membrane penetrating peptide and oligopeptide-1, but also the negative charge (anion) C-terminal of the cross-linked and fused new protein surface interacts with the positive charge (cation) N-terminal on HPV particles. Through the combination of the N-terminal of the positive charge on its surface with the negative charge of the hydrophobic region in the middle and the C-terminal of the recognition region site containing peptidase, the membrane translocation signal is coupled with the NLS of the nuclear localization signal, thus blocking the invasion of human papillomavirus into host cells. Through the interaction of cell membrane, it can penetrate the natural barrier of cell membrane and play a role in destroying the viral membrane shell to inactivate the virus, so as to prevent cervical precancerous lesions and treat HPV infection. PHPV fusion protein can repair damaged cells, enhance the elasticity of loose vaginal mucosa, tighten the inner wall of the vagina, improve the vaginal wetness, and reduce the vaginitis reaction.

For patients with early-stage non-small cell lung cancer (NSCLC) who cannot undergo surgery, stereotactic body radiotherapy (SBRT), also known as stereotactic ablative radiotherapy (SABR), usually achieves good therapeutic effects. This new treatment method has the characteristics of low toxicity and high efficacy for peripheral lung cancer. However, in central type lung cancer, especially in lesions near structures such as bronchial trees or mediastinum, there is an increased risk of severity. This review summarizes the following areas: (1) the methods and indications of using SBRT to treat NSCLC patients in different areas; (2) the principle and advantages and disadvantages of targeted MRI linear accelerators; (3) the diagnostic and evaluation process of targeted MRI linear accelerator therapy for lung cancer; (4) the clinical process of targeted MRI linear accelerator treatment for lung cancer; (5) tracking and monitoring of targeted MRI linear accelerator therapy for lung cancer; (6) pulmonary MRI disorders may include the following situations; (7) how to evaluate stage I-IV non-small cell lung cancer with targeted MRI linear accelerator; (8) how to locate central and peripheral lung cancer using targeted MRI linear accelerators; (9) increase safety of SBRT in central locations.